trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['destiny,lung,4', 't-dxd', 'lcsm,(-blcsm)', 'lung', 'destiny,lung 2']
destiny-lung 2: interim analysis of t-dxd 5.4 mg/kg and 6.4 mg/kg in her2 mutant (non-comparative trial). similar clinical activity, better toxicity profile. lower ild rate 14% &gt; 5.9% #esmo22 #lcsm 
Medical Oncology ?? HGU Gregorio Marañón?@myESMO Faculty ?? Lung Cancer - Mesothelioma - Thymoma?Power to the patients #endlungcancer #lcsm